Prognostic Significance of the Modified Glasgow Prognostic Score in Patients Undergoing FOLFOXIRI plus Bevacizumab Therapy for Advanced or Metastatic Colorectal Cancer

This is the authors' abstract. We don't add key points for this paper.

INTRODUCTION: The prognostic value of the modified Glasgow Prognostic Score (mGPS), a systemic inflammatory response marker, has been reported in various cancers. However, its role in patients with metastatic colorectal cancer (mCRC) undergoing first-line FOLFOXIRI + bevacizumab (BV) therapy remains unclear. In this study, we aimed to evaluate the prognostic significance of pretreatment mGPS and other inflammatory markers in this patient population. METHODS: This study retrospectively reviewed 133 patients with mCRC treated with first-line FOLFOXIRI + BV. We assessed the prognostic value of pretreatment mGPS and other inflammatory markers (neutrophil-to-lymphocyte, platelet-to-lymphocyte, and lymphocyte-to-monocyte ratios) in relation to progression-free survival (PFS) and overall survival (OS). RESULTS: Higher mGPS (score 2) was significantly associated with poor PFS and OS. Multivariate analysis identified mGPS 2 as an independent predictor of worse PFS (hazard ratio: 2.76, p = 0.004) and OS (hazard ratio: 3.43, p < 0.001). No significant associations were found between other inflammatory markers and survival outcomes. CONCLUSIONS: Pretreatment mGPS is a simple and useful prognostic factor for mCRC patients receiving FOLFOXIRI + BV therapy and may serve as a convenient indicator for accurate prognosis prediction and treatment decision-making.